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Mutations in the PARK2 gene have been implicated in the pathogenesis of early-onset
Parkinson’s disease. We present a case of movement disorder in a 4-year-old child from
consanguineous parents and with a family history of Dopamine responsive dystonia,
who was diagnosed with early-onset Parkinson’s disease based on initial identification
of a pathogenic PARK2 mutation. However, the evolution of the child’s clinical picture
was unusually rapid, with a preponderance of pyramidal rather than extrapyramidal
symptoms, leading to re-investigation of the case with further imaging and genetic
sequencing. Interestingly, a second homozygous mutation in the FA2H gene, implicated
in Hereditary spastic paraplegia, was revealed, appearing to have contributed to the
novel phenotype observed, and highlighting a potential interaction between the two
mutated genes.
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CASE BACKGROUND
A 4-year-old right-handed boy from Qatar presented with a 1-year history of increasingly frequent
falls and progressive gait abnormality. Pregnancy, birth, and neonatal development all proceeded
unremarkably. He sat independently by 6 months and walked by 13 months, although his parents
noted he did so “heavily” and on his tiptoes bilaterally. He was able to jump but not hop,
and negotiated staircases by holding onto the banisters. The parents had no concerns regarding
handwriting, cognition, behavior, vision, or hearing. Finally, no diurnal variation in the symptoms
had been noted.
The patient was one of three children born to healthy first cousins. His 3-year-old brother
and 18-month-old sister were both asymptomatic. His father’s 35-year-old brother presented with
dystonia aged 13 years. Although his genotype was untested, he was given a clinical diagnosis of
Dopamine-responsive dystonia (DRD), which remains Levodopa-responsive today.
The patient had already received a number of tests in Qatar. These included an MRI scan
6 months prior to presentation (reported as normal) and genetic sequencing of PARK2, a gene
well known to cause early-onset Parkinson’s disease (EO-PD) (1). Regarding the latter, PCR
amplification of exon 4 of PARK2 failed after several attempts, and subsequent MPLA analysis
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confirmed a homozygous, pathogenic deletion in exon 4 of the
PARK2 gene (p.Ala138Glyfs∗7), leading to a diagnosis of EO-
PD, with both parents subsequently identified as being carriers of
the same mutation (Figure 1). However, the patient underwent
two empirical trials of Levodopa without benefit, prompting the
parents to seek a second neurological opinion.
Examination (Video 1 in Supplementary Material) revealed
a markedly paretic gait, with the patient walking, without
festination or freezing, on his tiptoes with hips internally rotated
in a crouched posture. There was some dystonic posturing
of his limbs when lying on the couch. Both lower limbs
exhibited hypertonia and hyperreflexia with clonus and upgoing
plantars. His upper limbs were less affected, demonstrating subtle
rigidity, more pronounced on the left. There was no tremor and
no micrographia. There was subtle hypomimia. Cranial nerve
examination was normal. The patient followed instructions with
minor hesitation and interacted with his siblings normally.
In summary, the clinical picture was predominantly an
upper motor neuron-type deficit affecting the patient’s lower
limbs. In addition to lower limb pyramidal features, there were
less pronounced extrapyramidal features including dystonia in
the lower limbs, asymmetrical rigidity in the upper limbs,
and hypomimia. Hence, this was an early-onset, progressive
neurological disorder affecting multiple motor systems. The
predominance of pyramidal features, as well as the lack of
Levodopa response, argued against this being a disorder driven
purely by mutated PARK2.
DIAGNOSTIC INVESTIGATIONS
A repeat brain and spine MRI scan was performed under
general anesthetic. In contrast to the previous scan, this
demonstrated mildly increased T2 signal intensity in the
deep and periventricular white matter, predominantly in the
peritrigonal region of the lateral ventricles and the occipital
region of the cortex, consistent with leukodystrophy. In addition,
the repeat MRI demonstrated mild cerebellar volume loss, and
bilateral symmetrical iron deposition within the substantiae
nigrae and globus pallidi. These radiological changes progressed
over a one-year interval (Figure 2). A Dopamine Transporter
scan (DaTSCAN) was also carried out at the time of presentation
and was reported as normal (Figure 2).
A raft of neurometabolic tests were negative, including CSF
studies for neurotransmitters, pyridoxal phosphate and pterin
metabolites. Given the patient’s spastic paraparetic phenotype,
and the aboveMRI findings, an additional diagnosis of hereditary
spastic paraplegia (HSP) was considered.
DNA mutation analyses of a panel of HSP genes revealed
a homozygous, glycine to alanine substitution (c.786+1G>A)
following exon 5 of Fatty acid 2-hydroxylase (FA2H), a gene
responsible for the hydroxylation of myelin galactocerebroside
lipid components. In silico analysis of this mutation using
Human Splicing Finder software (URL: http://www.umd.be/
HSF3/, accessed on 04/04/2019) predicted it would alter an
essential “GU” splicing donor sequence of wild type FA2H
and should thus be considered pathogenic (2). Mutation of
FA2H leads to HSP35 (also known as SPG35), a disorder
characterized by childhood-onset spastic paraparesis (±dystonia,
ataxia, seizures, progressive cognitive decline) (3, 4) and T2 signal
hyperintensities on MRI± brain iron accumulation (5, 6).
MANAGEMENT
Treatments for HSP are currently limited to those providing
symptomatic benefit, alongside genetic counseling for the
family. Regular patient follow-up is also crucial, not only
to monitor response to symptomatic treatments, but also to
identify development of any of the clinically heterogeneous
features of HSP35. Furthermore, in this patient’s case, whilst
the negative DaTSCAN would argue against mutated PARK2-
related extrapyramidal features at time of presentation (which
were instead more likely to be caused by iron accumulation in the
basal ganglia secondary tomutated FA2H), it would be important
to continue to monitor for manifestation of mutated PARK2.
Indeed, 18 months after the initial presentation, worsening upper
limb rigidity was noted, along with bradykinesia, freezing effect,
and marked hypomimia, without significant changes in brain
iron accumulation on repeat MRI, prompting consideration of
a repeat DaTSCAN and levodopa trial at time of writing.
DISCUSSION
Ockham’s razor, a frequently cited diagnostic tool, argues that
“plurality should never be posited without necessity (7)”. In the
case above, the simplest explanation for the patient’s symptoms—
an altered gait and a propensity to fall—would have pointed to the
patient’s known recessive PARK2mutation.
However, there were elements within the history and
examination—particularly the pyramidal features and lack of
dopamine responsiveness—which could not be “shaved away”
for the sake of simplicity. Such features, along with symptom
progression, justified the repeat MRI scan, which held the key
to diagnosing the additional pathogenic FA2H mutation. The
phenotypic overlap demonstrated by this patient in relation to
the key clinical features of PARK2-related EO-PD and HSP35 is
outlined in Table 1 (9–12).
An additional point of interest remains the genotype of the
patient’s uncle, who was clinically diagnosed with DSD aged
13 without genotypic confirmation. An intriguing possibility
remains that the patient’s uncle in fact had homozygous
mutation of the PARK2 gene and was demonstrating features
of undiagnosed EO-PD (presenting closer to a typical age of
onset than in our patient). Certainly, there is considerable
phenotypic overlap between DRD and PARK2-related EO-PD
(7, 13), alongside the possibility of PARK2 mutations on both
maternal and paternal branches of the uncle’s family tree due to
undocumented consanguinity in previous generations.
At the genetic level, dual homozygous mutations in PARK2
and FA2H have not been reported previously in EO-PD.
Both genes play a role in mitochondrial function (a key
organelle in the regulation of cellular toxicity and death):
the former via a well-established role in optimal mitophagy,
the latter via recently discovered links between ceramide
metabolism, mitochondrial outer membrane permeability, and
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FIGURE 1 | Family tree illustrating the autosomal recessive inheritance of the PARK2 p.Ala138Glyfs*7 mutation, and the clinically affected family members at the time
of initial genetic testing.
FIGURE 2 | MRI and DaTSCAN images. Top row: Axial T2 weighted images and Sagittal T1 weighted image at age 4 years. Middle row: Axial T2 weighted images
Sagittal T1 weighted image at age 5 years. Lower panel: DaTSCAN. All MR images were acquired on a 1.5T scanner. The top and the middle row images show
progressive iron deposition in the globus pallidi, more than expected for age, and consistent with neuronal brain iron accumulation. There is global paucity of the
cerebral white matter with a thin corpus callosum. There is also cerebellar atrophy between the two time points. The DaTSCAN is normal.
electron transport chain activity (14–18). Dual mutation may
thus engender additional, or even synergistic, toxicity within
nigrostriatal neurons, which might lead to an earlier-than-
expected age of symptom onset (typically ∼20–40 years) (12,
19). Indeed, whilst the patient’s initial DaTSCAN was negative,
he went on to develop progressive parkinsonism without
corresponding changes in brain iron accumulation on interval
MRI suggesting clinical progression of the patient’s mutated
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TABLE 1 | Clinical features of PARK2-associated EO-PO and HSP35 and comparison to the patient studied (8–11).
PARK2-associated EO- PD HSP35 Patient
Mutation Pathogenic mutations in both alleles
of PARK2
Pathogenic mutations in both alleles of
FA2H
Homozygous mutations of FA2H
and PARK2
Age of onset Typically 20–40 years Childhood Motor abnormalities noted at ∼13 months
Progression Slowly-progressive (typically over decades) Variable but often rapid (frequently
wheelchair-dependent by early adulthood)
Rapid deterioration over months
Dopamine responsiveness Exquisite response No response No response
Pyramidal features Frequently have hyperreflexia Lower limb spasticity and weakness with
hyperreflexia, clonus, and upward plantars
Lower limb spasticity and weakness with
hyperreflexia, clonus, and upward plantars
Extrapyramidal features Parkinsonian features including rigidity,
tremor, bradykinesia, and hypomimia.
Dystonia and postural instability and
frequently prominent.
Frequently have dystonia Dystonia in the lower limbs, asymmetrical
rigidity in the upper limbs, and hypomimia
Other distinguishing features Less prevalent versus sporadic PD.
Anxiety may feature.
lntellectuaI decline, seizures, optic atrophy None clearly identified
MRI findings Often normal in early disease Periventricular white matter T2 signal
hyperintensities, cerebellar atrophy, iron
accumulation in the basal ganglia
Periventricular white matter T2 signal
hyperintensities, cerebellar atrophy, iron
accumulation in the basal ganglia
The patient demonstrates an overlapping phenotype with clinical features associated with both genetic mutations. Of note, the patient’s Parkinsonian phenotype appears earlier than
is typical for EO-PD, whilst the rate of clinical deterioration appears to be faster than is typically encountered with either EO-PD or HSP35 individuals, perhaps suggesting compound
toxicity of the two genetic mutations (see discussion).
PARK2-associated phenotype, and prompting consideration of a
repeat DaTSCAN and Levodopa trial.
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Video 1 | Demonstration of patient’s gait at time of presentation. Marked lower
limb spasticity is noted without festination or freezing. The patient walks on his
tiptoes with hips internally rotated.
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